Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00567229 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00567229: Clinical Trial Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00567229 is a Phase 2 study that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00567229, a Phase 2 study, was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
RATIONALE: Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving lenalidomide together with rituximab may be an effective treatment for multiple myeloma. PURPOSE: This phase II trial is studying the side effects of giving lenalidomide together with rituximab and to see how well it works in treating patients with recurrent or refractory multiple myeloma.
Interventions
- GENETIC microarray analysis
- OTHER laboratory biomarker analysis
- BIOLOGICAL rituximab
- DRUG lenalidomide
- OTHER flow cytometry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2007-11 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Why NCT00567229 stopped before completion
NCT00567229 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 5 interventions - of which microarray analysis is the first listed.
NCT00567229 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00567229 about?
NCT00567229 is a clinical study titled "Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma". RATIONALE: Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry c...
What is the current status of trial NCT00567229?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2007-11. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00567229?
The interventions under investigation include: microarray analysis (GENETIC), laboratory biomarker analysis (OTHER), rituximab (BIOLOGICAL), lenalidomide (DRUG), flow cytometry (OTHER).
Who is sponsoring clinical trial NCT00567229?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00567229's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia